Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Paul KnoeblSpero R Cataland Flora PeyvandiPaul CoppoMarie ScullyJohanna A Kremer HovingaAra MetjianJavier de la RubiaKaterina PavenskiJessica Minkue Mi EdouHilde De WinterFilip Callewaert

Published in: Journal of thrombosis and haemostasis : JTH (2019)

These results suggest that caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a disease exacerbation during double-blind treatment in HERCULES.

Keyphrases

chronic obstructive pulmonary disease
open label
clinical trial
double blind
phase iii
cystic fibrosis
phase ii
study protocol
placebo controlled
randomized controlled trial
phase ii study
combination therapy
radiation therapy